Navigation Links
Access Pharmaceuticals to Present at the Noble Financial Equity Conference
Date:8/13/2008

DALLAS, Aug. 13 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) announced today that it will make a presentation at the Fourth Annual Noble Financial Equity Conference to be held August 18-19, 2008 at the Loews Lake Las Vegas Resort, Nevada. Jeffrey B. Davis, CEO of Access is scheduled to speak on Monday, August 18, 2008 at 9:00 a.m. Pacific time (12:00 noon Eastern), and will give a corporate overview and discuss the Company's product pipeline and technologies.

The presentation will be webcast LIVE featuring high-definition, streaming video and PowerPoint slides. Access is available by logging on to the conference website http://www.noblemadmax.com or by going to the Company's website at http://www.accesspharma.com. It is recommended that interested parties register at least 15 minutes prior to the start of the presentation to ensure timely access.

About ProLindac(TM):

ProLindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin, which has sales in excess of $2 billion.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer and MuGard(TM) for the management of patients with oral mucositis. The Company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology b
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population
2. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
3. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
4. Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.
5. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
6. Access Pharmaceuticals Presents New Data at International Symposium Showing Companys Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
7. CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
8. A Perfect Storm Threatens Patient Access to Specialty Medical Care
9. AMT Makes Important Advance in the Development of its Gene Therapy for Hemophilia B -Company Accesses Technology to Prevent Immune Response
10. Access Licenses ProLindac(TM) to Jiangsu Aosaikang Pharmaceutical Co., LTD., a Leading Oncology Pharmaceutical Company for Manufacturing, Development and Commercialization in the Greater China Region
11. HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... ... June 26, 2015 , ... Claremont BioSolutions, LLC, ... have been integrated into a sample prep module intended to enable real-time quantitative ... of the NASA’s WetLab-2 Project. , On June 28, 2015, SpaceX CRS-7 will ...
(Date:6/26/2015)... ... June 26, 2015 , ... ... and a subsidiary of OraSure Technologies, Inc. (Nasdaq: OSUR) today announced that it ... part of its Gut Microbiome Grant Program. The company has awarded its ...
(Date:6/26/2015)... ... June 26, 2015 , ... ReliantHeart, Inc. , an ... from the first implant of the HeartAssist5® LVAD (HA5) to the 68th consecutive implant, ... , Thrombus that originates in an LVAD is referred to as de novo thrombus. ...
(Date:6/25/2015)... 2015 Research ... the addition of the  "2015 Market ... Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, ... Labs, POC Locations"  report to ... http://photos.prnewswire.com/prnh/20130307/600769) , A new ...
Breaking Biology Technology:Claremont BioSolutions’ SimplePrep™ Products Deployed in NASA Wetlab-2 Project Slated for June 28th Flight to International Space Station aboard SpaceX CRS-7 2Claremont BioSolutions’ SimplePrep™ Products Deployed in NASA Wetlab-2 Project Slated for June 28th Flight to International Space Station aboard SpaceX CRS-7 3DNA Genotek Inc. Announces Recipients of Gut Microbiome Grant Program 2DNA Genotek Inc. Announces Recipients of Gut Microbiome Grant Program 3HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 2HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 3Analysis of the Global Cancer Diagnostics Industry 2015-2020: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains 2Analysis of the Global Cancer Diagnostics Industry 2015-2020: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains 3
... 11 CV Therapeutics,Inc. (Nasdaq: CVTX ) today ... 2007 after the market closes on Tuesday, November 6,2007. ... p.m. EST,1:30 p.m. PST, on the company,s website. ... the Company,s website at, http://www.cvt.com and go to ...
... - The Board of,Directors of Immunotec Inc. is ... A. Northrop as President and Chief Executive Officer, ... Board of Directors of Immunotec Inc., Mr. Northrop ... success in rapid growth,situations, Mr. Northrop has impressive ...
... an Eden Prairie-,based molecular diagnostics service and technology company, ... its CFO, and Elizabeth A. Skinner,as VP - Legal, ... of Edwin Watts Golf, and has previously,served as VP ... Allied Signal,Aerospace, and corporate controller of NCR Corporation. He ...
Cached Biology Technology:CV Therapeutics To Announce 2007 Third Quarter Financial Results on Tuesday, November 6, 2007 2Immunotec Inc. announces appointment of President & CEO James A. Northrop 2Access Genetics Announces New Executive Appointments 2
(Date:6/16/2015)... , June 16, 2015 Fingerprint ... touch fingerprint sensors in the company,s portfolio from one of ... are planned to mainly take place during the third quarter ... Asia . Jörgen Lantto, CEO ... of    the   growing interest from smartphone OEMs in ...
(Date:6/15/2015)... YORK , June 15, 2015 ... today from Telstra reveals the majority of US consumers using ... them via biometrics, such as fingerprint and voiceprint, instead of ... According to Telstra,s " Mobile Identity   - ... " report, with smartphones now the primary channel used ...
(Date:6/11/2015)... 11, 2015 Daon, a global leader ... its IdentityX Mobile Authentication Platform v4.0 has been ... is an industry consortium launched in 2013 to ... stronger authentication.  In order to receive certification, a ... series of tests that measure compliance and ensure ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2
... Group, Inc. (OTC Bulletin Board: MDXG ), ... biomaterial-based products, announced today that its results for the ... and Company guidance will be released after the closing ... timing of the earnings announcement allows MiMedx time to ...
... the oocysts from the Cryptosporidium genus and cysts ... greatest public health problems in water supply, because these parasites ... Hermida, a scientist at the Galician Institute for Food Quality ... A team led by this researcher took 232 water samples ...
... at IRB Barcelona have completed the 3D structural sequence ... substances between the extra and intracellular milieu. This finding ... occur in these relevant proteins during basic cell processes, ... cell volume, and nerve transmission. The exchange ...
Cached Biology News:MiMedx Group, Inc. Announces Release Date for 2010 Fourth Quarter and Full Year Results 2Parasitic protozoons survive waste water and drinking water treatment plants in Galicia 2Researchers achieve a full film frame of a family of proteins essential for cell function 2
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
... for relax positively and negatively supercoiled DNA in ... , Studying the effects of supercoiling on transcription ... vitro , Determining the degree of supercoiling ... plasmids that differ in length by only one ...
Kit Components: Anti-PARP LumiGLO Chemiluminescent Substrate Immunoblot Blocking Reagent Pyronin Y Reagent Goat Anti-Rabbit IgG, HRP conjugate Double-It Reagent Film Exposure Folders Autor...
Biology Products: